Cardinal Health Recalls Alcohol Prep Pads Over Infection Risk Concerns
Cardinal Health has issued a voluntary nationwide recall of select lots of its Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol) after testing identified microbial contamination with Paenibacillus phoenicis. The recall extends to the consumer level and affects products distributed in the United States, Puerto Rico, and Japan between September 2025 and February 2026.
According to Cardinal Health, there is a reasonable probability that use of contaminated alcohol prep pads could result in local or systemic infections in vulnerable patients. Individuals with weakened immune systems, including patients undergoing chemotherapy or those with poorly controlled diabetes, may be at increased risk of developing serious infections such as bacteremia or central nervous system infections.
Webcol Alcohol Prep Pads are intended for external use and are commonly used to cleanse skin prior to injections, blood draws, and other medical procedures. Although the pads are not intended to be used on open wounds, contamination of products used for skin preparation can create opportunities for microorganisms to enter the body during invasive procedures.
The recalled products were distributed through healthcare facilities and other customers across multiple markets. Cardinal Health stated that affected customers were notified and instructed to review inventory, quarantine affected lots, notify downstream users, and return recall acknowledgment documentation.
Patients and healthcare providers are advised to discontinue use of affected products and follow Cardinal Health’s recall instructions.
Consumers who believe they may have experienced adverse effects associated with the recalled alcohol prep pads should contact their healthcare provider and report any adverse events through FDA’s MedWatch reporting system.
Why This Matters
Alcohol prep pads are widely used throughout healthcare settings and are generally considered low-risk products. However, contamination of products used to prepare skin prior to injections or other procedures can create significant risks for vulnerable patient populations.
This recall serves as a reminder that even simple healthcare products can become sources of patient harm when manufacturing or quality control failures introduce microbial contamination into the supply chain.
MDP Regulatory Intelligence Perspective
While alcohol prep pads are often viewed as routine healthcare supplies, this recall demonstrates the importance of robust manufacturing controls and microbiological quality assurance for products intended for patient contact.
The affected product is used in countless healthcare interactions every day, making contamination events particularly significant because of the large number of potential exposures. For quality and regulatory professionals, the recall highlights the continuing importance of contamination control, supplier oversight, complaint monitoring, and rapid field action processes when quality issues are identified.Read the Cardinal Health recall notice here.
Link
Read the Cardinal Health recall notice here.
When Preventable Diseases Return
Diseases once brought under control through vaccination have returned with devastating consequences. Historical outbreaks in the former Soviet Union and Japan offer important lessons as the United States confronts its largest measles resurgence in decades.For...
Intersurgical 22mm Smoothbore Breathing Tubes and Systems
FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...
FDA Early Alert: Teleflex/Arrow Guidewire
Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...
Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor
On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...
The Wolverine Peptide Stack: What We Know
Promoted for faster healing and injury recovery, two experimental peptides are attracting growing consumer interest despite limited human clinical evidence and unresolved safety questions.The promise sounds almost too good to be true: faster recovery from injuries,...
Hims & Hers Moves Into Selling Unapproved Peptides
Telehealth company's planned expansion illustrates how quickly commercial markets are responding to changes in federal oversight of experimental therapies.Hims & Hers Health plans to begin offering new wellness treatments in November, including an unapproved...
